

As filed with the Securities and Exchange Commission on May 3, 2022

Registration Statement No. 333-263326

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**Amendment No. 4 to**

**Form F-1  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

**OKYO Pharma Limited**

(Exact name of Registrant as specified in its charter)

**Not Applicable**

(Translation of Registrant's name into English)

**OKYO Pharma Limited  
Martello Court  
Admiral Park  
St. Peter Port  
Guernsey GY1 3HB**

**+44 (0)20 7495 2379**

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**Guernsey**

(State or other Jurisdiction of  
Incorporation or Organization)

**2836**

(Primary Standard Industrial  
Classification Code Number)

**Not Applicable**

(I.R.S. Employer  
Identification Number)

**OKYO Pharma US, Inc.  
420 Lexington Avenue, Suite 1405  
New York, NY 10170  
(917) 225-9646**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to:*

**Jeffrey Fessler  
Sheppard, Mullin, Richter & Hampton  
LLP  
30 Rockefeller Plaza  
New York, NY 10112-0015  
(212) 653 8700**

**Ed Lukins  
Ed Dyson  
Orrick, Herrington & Sutcliffe (UK)  
LLP  
107 Cheapside  
London EC2V 6DN  
United Kingdom  
+44 (0) 207 862 4620**

**Anthony J. Marsico  
Dorsey & Whitney LLP  
51 West 52nd Street  
New York, New York 10019  
(212) 415-9200**

**Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.



## PART II

### INFORMATION NOT REQUIRED IN PROSPECTUS

Unless otherwise indicated, all references to “OKYO” or the “company,” “we,” “our,” “us” or similar terms refer to OKYO Pharma Limited and its subsidiaries.

#### **Item 6. Indemnification of Directors and Officers.**

Pursuant to the company’s memorandum and articles of incorporation, the directors (including any alternate director), secretary and other officer or employee for the time being of the company shall be indemnified out of the assets of the company to the fullest extent permitted by the Companies (Guernsey) Law, 2008 from and against all actions, costs, charges, losses, damages and expenses in respect of which they may lawfully be indemnified which they or any of them shall or may incur or sustain by reason of any contract entered into or any act done, concurred in, or omitted, in or about the execution of their duty or supposed duty or in relation thereto.

#### **Item 7. Recent Sales of Unregistered Securities.**

The following list sets forth information regarding all unregistered securities issued by us since January 1, 2018 through the date of the prospectus that is a part of this registration statement:

- (i) On January 4, 2018, we issued 293,202 ordinary shares to Brad Mills, 432,820 ordinary shares to Gerard Holden, 338,808 ordinary shares to Jim Mellon, 307,100 ordinary shares to Willy Simon, 307,100 shares to Andrew Gutmann and 5,558,549 to BurnBrae, all in lieu of directors fees of £175,673, at a price of between £0.022 and £0.025 per ordinary share, following which we had 388,395,417 ordinary shares in issue.
- (ii) On May 1, 2018, we issued 135,000,000 ordinary shares to Panetta Partners Ltd. to acquire OK-101 and OK-201 at a price of £0.015 per ordinary share, in lieu of consideration of £2,025,000, following which we had 523,395,417 ordinary shares in issue.
- (iii) On May 22, 2018, we issued 200,000 ordinary shares to Shore Capital in consideration of a corporate finance fee, at a price of £0.0125 per ordinary share, in lieu of fees of £2,500, following which we had 524,108,283 ordinary shares in issue.

- (iv) On October 22, 2018, we issued 512,866 ordinary shares to Kopin & Co. at a price of £0.015 per ordinary share as part of an amendment to a collaboration agreement with On Target Therapeutics LLC., following which we had 88,933,928 ordinary shares in issue.
- (v) On May 22, 2019, we issued 36,363,636 ordinary shares to Panetta Partners Ltd. by way of a placing of ordinary shares to raise £400,000, at a price of £0.011 per ordinary share, following which we had 560,471,919 ordinary shares in issue.
- (vi) On March 24, 2020, we issued 40,000,000 ordinary shares to Veneto Seed Ventures Ltd. and 35,825,130 to Panetta Partners Ltd. by way of a placing of ordinary shares to raise £379,126, at a price of £0.0055 per ordinary share, following which we had 636,297,049 ordinary shares in issue.
- (vii) On May 29, 2020, we raised £440,000 through the issue of convertible loan notes which carry an interest rate of 20% compounding and have maximum term of 4 years. The convertible loan notes convert into ordinary shares at a price of £0.004 per share and, if converted, the shares will be issued with a warrant attached at an exercise price of £0.004, with a maximum life of 5 years from the date of issue of the convertible loan notes, regardless of the conversion date).
- (viii) On June 5, 2020, we issued 36,269,253 ordinary shares to Panetta Partners Ltd. by way of a placing of ordinary shares to raise £181,346 at a price of £0.0055 per ordinary share, following which we had 672,566,302 ordinary shares in issue.
- (ix) On July 27, 2020, we raised £3,500,000 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term of 3 years. The convertible loan notes convert into ordinary shares at a price of £0.085 per share.
- (x) On August 17, 2020, we raised £1,437,104 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term of 3 years. The convertible loan notes convert into ordinary shares at a price of £0.085 per share.
- (xi) On September 3, 2020, we raised £500,000 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term of 3 years. The convertible loan notes convert into ordinary shares at a price of £0.085 per share.
- (xii) On May 7, 2021, we issued 36,363,636 ordinary shares to Panetta Partners Ltd. through the exercise of warrants to raise £490,909 at a price of £0.00135 per ordinary share, following which we had 709,179,938 ordinary shares in issue.
- (xiii) On May 7, 2021, we issued 72,000,000 ordinary shares to Panetta Partners Ltd. through the exercise of warrants to raise £396,000 at a price of £0.0055 per ordinary share, following which we had 781,179,938 ordinary shares in issue.
- (xiv) On May 7, 2021, we issued 25,920,000 ordinary shares to Panetta Partners Ltd. through the conversion of convertible loan notes, following which we had 807,099,938 ordinary shares in issue.
- (xv) On May 7, 2021, we issued 22,000,000 ordinary shares to Mayflower Medical Ventures. through the conversion of convertible loan notes, following which we had 829,099,938 ordinary shares in issue.
- (xvi) On May 7, 2021, we issued 15,000,000 ordinary shares to Babington Microcap. through the conversion of convertible loan notes, following which we had 844,099,938 ordinary shares in issue.
- (xvii) On May 7, 2021, we issued 18,329,093 ordinary shares to Planwise Ltd. through the conversion of convertible loan notes, following which we had 862,049,031 ordinary shares in issue.
- (xviii) On May 7, 2021, we issued 25,079,922 ordinary shares to Laura Fonda. through the conversion of convertible loan notes, following which we had 887,508,953 ordinary shares in issue.
- (xix) On May 7, 2021, we issued 17,112,557 ordinary shares to Morris Silverman. through the conversion of convertible loan notes, following which we had 904,621,510 ordinary shares in issue.
- (xx) On May 7, 2021, we issued 16,144,722 ordinary shares to Howard Freedberg. through the conversion of convertible loan notes, following which we had 920,766,232 ordinary shares in issue.
- (xxi) On May 7, 2021, we issued 3,573,888 ordinary shares to Carmine Rotandaro. through the conversion of convertible loan notes, following which we had 924,340,120 ordinary shares in issue.

- (xxii) On May 7, 2021, we issued 6,269,980 ordinary shares to John Storey. through the conversion of convertible loan notes, following which we had 930,610,100 ordinary shares in issue.
- (xxiii) On May 7, 2021, we issued 470,248 ordinary shares to Optiva. through the conversion of convertible loan notes, following which we had 931,080,348 ordinary shares in issue.
- (xxiv) On May 7, 2021, we issued 25,920,000 ordinary shares to Panetta Partners Ltd. through the exercise of warrants to raise £103,680 at a price of £0.004 per ordinary share, following which we had 957,000,348 ordinary shares in issue
- (xxv) On May 7, 2021, we issued 13,685,760 ordinary shares to Planwise Ltd through the exercise of warrants to raise £54,743 at a price of £0.004 per ordinary share, following which we had 970,686,108 ordinary shares in issue.
- (xxvi) On February 24, 2022, we issued 46,500,000 ordinary shares to Mayflower Medical Ventures. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,017,186,108 ordinary shares in issue
- (xxvii) On February 24, 2022, we issued 68,500,000 ordinary shares to Saviese Generation Limited. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,085,686,108 ordinary shares in issue
- (xxviii) On February 24, 2022, we issued 48,224,320 ordinary shares to Toro Chimica Ventures Limited. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,133,910,428 ordinary shares in issue
- (xxviii) On February 24, 2022, we issued 39,982,880 ordinary shares to Babington Microcap. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,173,893,308 ordinary shares in issue
- (xxvix) On February 24, 2022, we issued 68,500,000 ordinary shares to Garcer Ventures Limited. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,242,393,308 ordinary shares in issue
- (xxvix) On February 24, 2022, we issued 24,112,160 ordinary shares to High Octane. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,266,505,468 ordinary shares in issue
- (xxvix) On February 24, 2022, we issued 68,500,000 ordinary shares to PPIH Ltd. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,335,005,468 ordinary shares in issue
- (xxvix) On February 24, 2022, we issued 39,400,000 ordinary shares to Scion Sciences Limited. through the conversion of convertible loan notes and the cashless exercise of warrants, following which we had 1,374,415,468 ordinary shares in issue

None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act (and Regulation S promulgated thereunder), or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.

**Item 8. Exhibits and Financial Statement Schedules.**

**ITEM 19: EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
1.1**	<a href="#"><u>Form of Underwriting Agreement</u></a>
3.1**	<a href="#"><u>Memorandum and Articles of Incorporation of OKYO Pharma Limited</u></a>
2.1**	<a href="#"><u>Form of Deposit Agreement.</u></a>
2.2**	<a href="#"><u>Form of American Depositary Receipt (included in Exhibit 2.1).</u></a>
5.1**	<a href="#"><u>Opinion of Carey Olsen (Guernsey) LLP</u></a>
10.1**	<a href="#"><u>OKYO Pharma Limited Share Option Plan With Non-Employee Sub-Plan And US Sub-Plan</u></a>
10.2**	<a href="#"><u>Executive Employment Agreement dated December 21, 2020 between Gary S. Jacob and OKYO Pharma Limited as amended on January 19, 2021.</u></a>
10.3**	<a href="#"><u>Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated June 4, 2018</u></a>
10.4**	<a href="#"><u>Amendment to Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated October 22, 2018</u></a>
10.5**	<a href="#"><u>License Agreement dated as of May 1, 2018 by and between Tufts Medical Center, Inc. and OKYO Pharma Limited</u></a>
10.6**	<a href="#"><u>Shared Services Agreement dated as of January 1, 2018 by and between OKYO Pharma Limited and Tiziana Life Sciences plc</u></a>
10.7**	<a href="#"><u>License and Sublicense Agreement dated May 22, 2017 by and between On Target Therapeutics, LLC and OKYO Pharma Limited</u></a>
10.8**	<a href="#"><u>First Amendment to the License and Sublicense Agreement dated March 25, 2021 by and between On Target Therapeutics, LLC and OKYO Pharma Limited.</u></a>
10.9**	<a href="#"><u>Collaboration Agreement dated August 6, 2019 between Tufts Medical Center, Inc. and OKYO Pharma Limited.</u></a>
10.10**	<a href="#"><u>Amendment No. 1 to Collaboration Agreement dated November 10, 2020 between Tufts Medical Center, Inc. and OKYO Pharma Limited.</u></a>
10.11**	<a href="#"><u>Letter of Appointment between OKYO Pharma Limited and Gabriele Cerrone dated January 6, 2021</u></a>
10.12**	<a href="#"><u>Letter Agreement between OKYO Pharma Limited and Gabriele Cerrone dated April 28, 2021</u></a>
21.1**	<a href="#"><u>List of Subsidiaries.</u></a>
23.1	<a href="#"><u>Consent of Mazars LLP, independent registered public accountants regarding the financial statements of OKYO Pharma Limited as of March 31, 2020 and 2019 and for each of the years then ended.</u></a>
23.2**	<a href="#"><u>Consent of Carey Olsen (Guernsey) LLP (included in Exhibit 5.1)</u></a>
24.1**	<a href="#"><u>Power of Attorney (included on signature page)</u></a>
107**	<a href="#"><u>Filing Fee Table</u></a>

**\*\* Previously filed.**

## Financial Statement Schedules.

All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or the notes thereto.

## Item 9. Undertakings.

- (a) The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.
- (b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
- (c) The undersigned registrant hereby undertakes that:
  - (1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.
  - (2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on the 3rd day of May, 2022.

### OKYO PHARMA LIMITED

By: /s/ Gary S. Jacob

Gary S. Jacob

Chief Executive Officer and Director

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Date</u>
<u>*</u> Gabriele Cerrone Non-Executive Chairman	May 3, 2022
<u>/s/ Gary S. Jacob</u> Gary S. Jacob Chief Executive Officer and Director	May 3, 2022
<u>*</u> Keeren Shah Chief Financial Officer	May 3, 2022
<u>*</u> Willy Simon Director	May 3, 2022
<u>*</u> John Brancaccio Director	May 3, 2022
<u>*</u> Bernard Denoyer Director	May 3, 2022

### OKYO Pharma US, Inc.

By: /s/ Gary S. Jacob

Name: Gary S. Jacob

Title: Director

Authorized U.S. Representative

May 3, 2022

\*By: /s/ Gary S. Jacob

Gary S. Jacob

Attorney-in-Fact